NCT07006077 - Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

February 21, 2026

Study Completion Date

June 5, 2026

Conditions

Advanced Pancreatic Cancer

Interventions

BIOLOGICAL

Recombinant human IL-21-expressing oncolytic vaccinia virus injection

hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.

Trial Locations (1)

Unknown

RECRUITING

Affiliated Hangzhou First People's Hospital,School of Medicine,Westlake University, Hangzhou

All Listed Sponsors

lead

Hangzhou Converd Co., Ltd.

INDUSTRY